Non-fasting reference intervals for the Abbott IMx(TM) homocysteine and AxSYM(TM) plasma folate assays: Influence of the methylenetetrahydrofolate reductase 677 C→T mutation on homocysteine

Annals of Clinical Biochemistry

Volumn 37, Issue 3, 2000, Pages 390-398

  Donnelly, James G ^a,b   Isotalo, Phillip A ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; MULTIVITAMIN; VITAMIN B GROUP;

ARTICLE; DIET SUPPLEMENTATION; FEMALE; FOLIC ACID BLOOD LEVEL; GENE MUTATION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLISM; NORMAL HUMAN; NUTRITION; PRIORITY JOURNAL; REFERENCE VALUE; SEX DIFFERENCE;

EID: 0034088896     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563001899339     Document Type: Article

References (28)

1. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8
2. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996; 143: 845-59
3. Dawson DW, Waters HM. Malnutrition: folate and cobalamin deficiency. Br J Biomed Sci 1994; 51: 221-7
4. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21
5. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation [letter]. Am J Hum Genet 1998; 62: 1258-60
6. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3
7. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996; 94: 2154-8
8. Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WD, Taylor LM Jr, et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996; 94: 3074-8
9. Donnelly JG, Rock G. Genetic determinants of heritable venous thrombosis: Genotyping methods for factor V Leiden A1691G, methylenetetrahydrofolate reductase C677T, prothrombin G20210A mutation and algorithms for venous thrombosis investigations. Clin Biochem 1999; 32: 223-8
10. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atheroselerosis 1995; 116: 147-51
11. Candito M, Bedoucha P, Gibelin P, Jambou D, de Franchis R, Sadoul JL, et al. Fasting, postprandial, and post-methionine-load homocysteinemia and methyleneletrahydrofolate reductase polymorphism in vascular disease. J Inherit Metab Dis 1999; 22: 588-92
12. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81
13. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6
14. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57
15. Munro HN. Amino acid requirements and metabolism and their relevance to parenteral nutrition. In: Wilkinson AW, ed. Parenteral Nutrition. London: Churchill Livingstone, 1972: 34-67
16. Mudd SH, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism 1975; 24: 721-35
17. Brattstrom L, Israelsson B, Hultberg B. Plasma homocysteine and methionine tolerance in early-onset vascular disease. Haemostasis 1989; 19(Suppl 1): 35-44
18. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6
19. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996; 123: 193-202
20. Green JM, Ballou DP, Matthews RG. Examination of the role of methylenetetrahydrofolate reductase in incorporation of methyltetrahydrofolate into cellular metabolism. FASEB J 1988; 2: 42-7
21. Strum WB, Liem HH. Hepatic uptake, intracellular accumulation and biliary secretion of 5-methyltetrahydrofolate. Res Commun Chem Pathol Pharmacol 1980; 30: 493-507
22. Strum WB, Hanstein WG. Pharmacokinetics of 5-methyltetrahydrofolate. Res Commun Chem Pathol Pharmacol 1978; 20: 449-56
23. Strum WB. Enzymatic reduction and methylation of folate following pH-dependent, carrier-mediated transport in rat jejunum. Biochim Biophys Acta 1979; 554: 249-57
24. Hillman RS, McGuffin R, Campbell C. Alcohol interference with the folate enterophepatic cycle. Trans Assoc Am Phys 1977; 90: 145-56
25. Steinberg GS, Campbell CL, Hillman RS. Kinetics of the normal folate enterohepatic cycle. J Clin Invest 1979; 64: 83-8
26. van der Put NM, Steegers TR, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, et al. Mutated methylenetetrahydrofolate reductasc as a risk factor for spina bifida. Lancet 1995; 346: 1070-1
27. Brouwer JD, Welten EH, Reijngoud DJ, van Doormaal JJ, Muskiet FA. Plasma folic acid cutoff value, derived from its relationship with homocyst(e)ine. Clin Chem 1998; 44: 1545-50
28. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9